Get the Stockscreener App
11.26
3.84%
-0.45
Compass Pathways Plc Adr stock is traded at $11.26, with a volume of 3.62M.
It is down -3.84% in the last 24 hours and down -10.49% over the past month.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
See More
Previous Close:
$11.71
Open:
$11.82
24h Volume:
3.62M
Relative Volume:
0.84
Market Cap:
$1.52B
Revenue:
-
Net Income/Loss:
$-191.97M
P/E Ratio:
-3.5661
EPS:
-3.1575
Net Cash Flow:
$-159.63M
1W Performance:
-8.83%
1M Performance:
-10.49%
6M Performance:
+57.04%
1Y Performance:
+157.67%
1-Day Range:
$11.01
$11.89
1-Week Range:
$11.01
$12.39
52-Week Range:
$3.92
$15.40
Compass Pathways Plc Adr Stock (CMPS) Company Profile
Name
Compass Pathways Plc Adr
Sector
Industry
Phone
1-716-676-6461
Address
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, DVA, FMS, EHC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
11.26 | 1.52B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
382.19 | 84.78B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
233.20 | 20.09B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
235.44 | 15.11B | 13.84B | 1.10B | 1.49B | 10.42 |
FMS
Fresenius Medical Care Ag Adr
|
24.59 | 13.21B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
112.89 | 11.20B | 6.07B | 793.80M | 464.40M | 5.9914 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | B. Riley Securities | Buy |
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-23-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-27-25 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-01-24 | Initiated | Morgan Stanley | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-22 | Resumed | Berenberg | Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Oct-29-21 | Initiated | Oppenheimer | Outperform |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
| May-11-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-01-21 | Initiated | ROTH Capital | Buy |
| Oct-14-20 | Initiated | H.C. Wainwright | Buy |
| Oct-13-20 | Initiated | Berenberg | Buy |
| Oct-13-20 | Initiated | Canaccord Genuity | Buy |
| Oct-13-20 | Initiated | Cowen | Outperform |
| Oct-13-20 | Initiated | Evercore ISI | Outperform |
View All
Compass Pathways Plc Adr Stock (CMPS) Latest News
COMPASS Pathways plc (CMPS) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Sahm
Why Is Neuronetics Stock Soaring Monday? - Sahm
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - Sahm
Compass Pathways study shows minimal interaction in psilocybin trials By Investing.com - Investing.com South Africa
Compass Pathways study shows minimal interaction in psilocybin trials - Investing.com
Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors? - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock falls on Phase 3 trial data release By Investing.com - Investing.com South Africa
Compass Pathways stock falls on Phase 3 trial data release - Investing.com
Compass Pathways reports 6-month data from phase 3 TRD trial - Investing.com
Why is Compass Pathways stock gaining today? By Investing.com - Investing.com South Africa
Why is Compass Pathways stock gaining today? - Investing.com
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Enterprise value to EBIT forward of COMPASS Pathways Plc Sponsored ADR – MUN:5Y6 - TradingView
Compass Pathways stock hits 52-week high at 14.77 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 14.77 USD - Investing.com
COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS) - TradingView
Why is Compass Pathways stock being clobbered today? - Investing.com
Compass Pathways earnings on deck as psychedelic approval nears - Investing.com
Why is Compass Pathways stock surging 9% today? By Investing.com - Investing.com India
Why is Compass Pathways stock surging 9% today? - Investing.com
Compass Pathways stock hits 52-week high at 12.48 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 12.48 USD - Investing.com
Compass Pathways elects Kathleen Tregoning to board By Investing.com - Investing.com South Africa
Compass Pathways elects Kathleen Tregoning to board - Investing.com
CMPSCompass Pathways Plc ADR Stock Price and Quote - Finviz
COMPASS Pathways Plc Q1 2026 Earnings: Narrower Loss Provides Hope Amid Pre-Revenue StageLow Growth Earnings - Newser
Wolfe Research initiates Compass Pathways stock with outperform rating - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD By Investing.com - Investing.com India
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins - Yahoo Finance
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Sahm
Is Compass Pathways (CMPS) outperforming other medical stocks this year? - MSN
Compass Pathways Reports Strong Q1 Results, Shares Surge - Sahm
Why COMPASS Pathways (CMPS) Is Up 13.1% After FDA Fast-Track Moves For COMP360 Profit Shift - Sahm
Compass Pathways stock hits 52-week high at 10.22 USD - Investing.com India
Compass Pathways Q1 Earnings Call Highlights - Barchart.com
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review - Investing.com India
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review By Investing.com - Investing.com South Africa
What makes COMPASS Pathways PLC sponsored ADR (CMPS) a strong momentum stock: Buy now? - MSN
Compass Pathways Plc Adr Stock (CMPS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):